Trial Profile
A Study to Evaluate the Safety and Efficacy of Sorafenib Maintenance after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients With FLT3-ITD Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Apr 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 07 Apr 2017 Results published in the Cancer
- 03 Mar 2016 New trial record